Delcath Systems to Present at the 34th Annual Roth Conference

Rhea-AI Summary

Delcath Systems, Inc. (DCTH) will present at the 34th annual Roth Conference on March 14, 2022, at 3:30 PM PT. The presentation focuses on the company's innovative treatment for liver cancers, specifically the percutaneous hepatic perfusion (PHP) system, known as HEPZATO in the U.S. for metastatic ocular melanoma. In Europe, this system is marketed as CHEMOSAT. A webcast of the presentation will be available online. For further inquiries or one-on-one meetings, interested parties are encouraged to contact Delcath's investor relations.

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will present at the 34^th annual Roth Conference on Monday, March 14, 2022, at 3:30 PM PT. A webcast of the presentation will be available at: https://wsw.com/webcast/roth43/dcth2/1882196  

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, for the treatment of metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

What is the date and time of Delcath Systems' presentation at the Roth Conference?

Delcath Systems will present on March 14, 2022, at 3:30 PM PT.

Where can I watch Delcath Systems' presentation at the Roth Conference?

You can watch the presentation live through their webcast available online.

What is the focus of Delcath Systems' presentation at the conference?

The presentation focuses on the percutaneous hepatic perfusion (PHP) system for treating liver cancers.

What is HEPZATO and where is it used?

HEPZATO is Delcath's PHP system used in the U.S. for treating metastatic ocular melanoma.

What is CHEMOSAT and its significance in Europe?

CHEMOSAT is the European name for Delcath's PHP system, approved for treating various liver cancers.